CytRx Competitors

CytRx (OTCMKTS:CYTR) and Gritstone Oncology (NASDAQ:GRTS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares CytRx and Gritstone Oncology's gross revenue, earnings per share and valuation.

CytRx has higher earnings, but lower revenue than Gritstone Oncology.

Institutional and Insider Ownership

0.0% of CytRx shares are held by institutional investors. Comparatively, 59.0% of Gritstone Oncology shares are held by institutional investors. 22.0% of CytRx shares are held by insiders. Comparatively, 38.0% of Gritstone Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

CytRx has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for CytRx and Gritstone Oncology, as provided by MarketBeat.com.

Gritstone Oncology has a consensus price target of $22.3333, indicating a potential upside of 61.02%. Given Gritstone Oncology's higher probable upside, analysts plainly believe Gritstone Oncology is more favorable than CytRx.

Profitability

This table compares CytRx and Gritstone Oncology's net margins, return on equity and return on assets.

Summary

CytRx beats Gritstone Oncology on 6 of the 11 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Fusion Pharmaceuticals and CytRx's gross revenue, earnings per share and valuation.

CytRx has higher revenue and earnings than Fusion Pharmaceuticals.

Insider and Institutional Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of CytRx shares are owned by institutional investors. 22.0% of CytRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Fusion Pharmaceuticals and CytRx's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Fusion Pharmaceuticals and CytRx, as reported by MarketBeat.

Fusion Pharmaceuticals currently has a consensus target price of $24.3333, indicating a potential upside of 120.61%. Given Fusion Pharmaceuticals' higher probable upside, research analysts clearly believe Fusion Pharmaceuticals is more favorable than CytRx.

Summary

Fusion Pharmaceuticals beats CytRx on 5 of the 8 factors compared between the two stocks.

CytRx (OTCMKTS:CYTR) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares CytRx and Harpoon Therapeutics' top-line revenue, earnings per share and valuation.

CytRx has higher earnings, but lower revenue than Harpoon Therapeutics.

Risk and Volatility

CytRx has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of CytRx shares are held by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are held by institutional investors. 22.0% of CytRx shares are held by insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares CytRx and Harpoon Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CytRx and Harpoon Therapeutics, as reported by MarketBeat.

Harpoon Therapeutics has a consensus target price of $31.5714, indicating a potential upside of 74.14%. Given Harpoon Therapeutics' higher possible upside, analysts clearly believe Harpoon Therapeutics is more favorable than CytRx.

Summary

Harpoon Therapeutics beats CytRx on 6 of the 11 factors compared between the two stocks.

AVROBIO (NASDAQ:AVRO) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Insider and Institutional Ownership

86.7% of AVROBIO shares are held by institutional investors. Comparatively, 0.0% of CytRx shares are held by institutional investors. 4.8% of AVROBIO shares are held by company insiders. Comparatively, 22.0% of CytRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares AVROBIO and CytRx's net margins, return on equity and return on assets.

Risk and Volatility

AVROBIO has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, CytRx has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500.

Valuation & Earnings

This table compares AVROBIO and CytRx's revenue, earnings per share and valuation.

CytRx has higher revenue and earnings than AVROBIO.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AVROBIO and CytRx, as provided by MarketBeat.com.

AVROBIO currently has a consensus price target of $27.8333, suggesting a potential upside of 142.87%. Given AVROBIO's higher possible upside, research analysts plainly believe AVROBIO is more favorable than CytRx.

Summary

AVROBIO beats CytRx on 5 of the 9 factors compared between the two stocks.

Cellular Biomedicine Group (NASDAQ:CBMG) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

22.0% of Cellular Biomedicine Group shares are owned by institutional investors. Comparatively, 0.0% of CytRx shares are owned by institutional investors. 8.5% of Cellular Biomedicine Group shares are owned by company insiders. Comparatively, 22.0% of CytRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Cellular Biomedicine Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, CytRx has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Cellular Biomedicine Group and CytRx, as provided by MarketBeat.com.

Cellular Biomedicine Group currently has a consensus price target of $19.00, suggesting a potential downside of 3.80%. Given Cellular Biomedicine Group's higher probable upside, equities analysts plainly believe Cellular Biomedicine Group is more favorable than CytRx.

Earnings and Valuation

This table compares Cellular Biomedicine Group and CytRx's gross revenue, earnings per share and valuation.

CytRx has lower revenue, but higher earnings than Cellular Biomedicine Group.

Profitability

This table compares Cellular Biomedicine Group and CytRx's net margins, return on equity and return on assets.

Summary

CytRx beats Cellular Biomedicine Group on 5 of the 9 factors compared between the two stocks.

CytRx (OTCMKTS:CYTR) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Valuation and Earnings

This table compares CytRx and Freeline Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Freeline Therapeutics has lower revenue, but higher earnings than CytRx.

Insider & Institutional Ownership

0.0% of CytRx shares are held by institutional investors. Comparatively, 38.5% of Freeline Therapeutics shares are held by institutional investors. 22.0% of CytRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for CytRx and Freeline Therapeutics, as provided by MarketBeat.com.

Freeline Therapeutics has a consensus price target of $26.00, indicating a potential upside of 79.43%. Given Freeline Therapeutics' higher possible upside, analysts clearly believe Freeline Therapeutics is more favorable than CytRx.

Profitability

This table compares CytRx and Freeline Therapeutics' net margins, return on equity and return on assets.

Summary

Freeline Therapeutics beats CytRx on 5 of the 7 factors compared between the two stocks.